RxDoctor Payments DataLook up a doctor →

Christina Nguyen, MD

Neuromuscular Medicine · Fountain Valley, CANPI 1508186701

Payments from drug & device makers

$32,381in general payments, 2019–2025

Across 1,755 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • UCB, Inc.$2K
  • Acadia Pharmaceuticals Inc$2K
  • Novartis$2K
  • Neurocrine Biosciences, Inc.$2K
  • Biogen$1K
  • plus $20K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)239$4,524
UCB, Inc.93$1,949
Acadia Pharmaceuticals Inc90$1,588
Novartis120$1,562
Neurocrine Biosciences, Inc.81$1,524
Biogen68$1,333
MDD US Operations, LLC36$1,326
Ipsen Biopharmaceuticals, Inc53$1,232
SK Life Science, Inc.59$1,163
AstraZeneca(2 entities)48$1,144
Amneal Pharmaceuticals LLC53$1,104
Teva Pharmaceuticals USA, Inc.70$1,101
Merz Pharmaceuticals, LLC56$1,097
Eisai Inc.57$919
Sunovion Pharmaceuticals Inc.62$847
Kyowa Kirin, Inc.46$739
CSL Behring28$609
Pfizer39$555
Supernus Pharmaceuticals, Inc.23$535
Acorda Therapeutics, Inc38$494
Amgen27$481
Medtronic(2 entities)13$468
Sumitomo Pharma America, Inc.20$417
Merz North America, Inc.29$381
Avion Pharmaceuticals25$352
GE HealthCare16$334
Lilly USA, LLC19$320
Adamas Pharmaceuticals, Inc.24$297
Biohaven Pharmaceutical Holding Company Ltd.20$283
Sanofi14$270
Takeda Pharmaceuticals U.S.A., Inc.16$255
Bristol Myers Squibb13$238
Lundbeck LLC12$203
Argenx US, Inc.8$195
Catalyst Pharmaceuticals, Inc.11$188
TG Therapeutics, Inc.7$175
Banner Life Sciences, LLC10$148
Biohaven Pharmaceuticals, Inc.11$147
Grifols USA, LLC7$137
Boston Scientific6$126
Avanir Pharmaceuticals, Inc.7$124
Tanabe Pharma America, Inc.7$119
Johnson & Johnson(2 entities)8$119
Greenwich Biosciences, Inc.2$114
Azurity Pharmaceuticals, Inc.5$105
Vertical Pharmaceuticals, LLC6$104
Bayer5$90
Abbott5$78
Jazz Pharmaceuticals Inc.4$78
Neurelis, Inc.5$77
Akcea Therapeutics, Inc.4$70
Arbor Pharmaceuticals, Inc.3$65
Octapharma USA, Inc.2$56
Axsome Therapeutics, Inc.2$54
Revance Therapeutics, Inc.3$52
EMD Serono, Inc.3$48
Pharmacyclics LLC, An Abbvie Company2$45
Mallinckrodt Enterprises LLC2$43
Averitas Pharma Inc.1$30
Portola Pharmaceuticals, LLC2$28

How this compares

$32,381 in reported general payments places this provider in the 60th percentile of 44 neuromuscular medicine providers in California.

See all neuromuscular medicine providers in California →

Medicare billing

Part B allowed, 2024
$227,617
Medicare patients
294
Services billed
17,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromuscular medicine in Fountain Valley

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →